Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06374186 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City

A NA study, sponsored by University of Missouri, Kansas City.

Completed
Registry status
NA
Development phase
26
Enrollment target

NCT06374186: Completed NA study, sponsored by University of Missouri, Kansas City.

NCT06374186 is a NA study that has completed, run by University of Missouri, Kansas City. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06374186, a NA study, has completed, sponsored by University of Missouri, Kansas City.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target

Study Summary

This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases individual adherence to a diabetes treatment plan and improves blood sugar management.

Primary Outcome

Percent time with blood glucose between 70 to 180 mg/dL

Interventions

  • BEHAVIORAL Control
  • BEHAVIORAL Behavioral Intervention with financial rewards and coaching

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2024-05-01
Est. Completion 2025-08-12
Phase NA

What the finished NCT06374186 record still lists

NCT06374186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT06374186 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06374186 about?

NCT06374186 is a clinical study titled "Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City". This study is evaluating a behavioral treatment program that uses diabetes coaching and financial rewards in addition to continuous glucose monitoring to improve diabetes management in adult patients with type 2 diabetes. This study will evaluate if this behavioral treatment program increases indivi...

What is the current status of trial NCT06374186?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2024-05-01. Estimated completion is 2025-08-12.

What interventions are being tested in trial NCT06374186?

The interventions under investigation include: Control (BEHAVIORAL), Behavioral Intervention with financial rewards and coaching (BEHAVIORAL).

Who is sponsoring clinical trial NCT06374186?

This trial is sponsored by University of Missouri, Kansas City, which has 33 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06374186's enrollment target sits among peer trials

26 1710th of 2000 higher than 289 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06374186, the US trial registry maintained by the National Library of Medicine. NCT06374186 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.